Plasma carnitine and lipid-lowering drugs

Area of Science:

• Biochemistry
• Pharmacology
• Lipid Metabolism

Background:

• Oral carnitine is known to reduce lipids and increase high-density lipoprotein cholesterol (HDL-C).
• Carnitine levels may be affected by lipid-lowering drug combinations.

Purpose of the Study:

• To investigate the effect of a probucol and clofibrate combination on plasma carnitine levels and HDL-C.
• To determine the relationship between carnitine levels and clofibrate therapy.

Main Methods:

• Observational study of subjects receiving probucol and clofibrate.
• Measurement of plasma carnitine and HDL-C levels.
• Analysis of carnitine level changes with drug cessation.

Main Results:

• Subjects on combination therapy showed unexpectedly high basal carnitine concentrations.
• Elevated carnitine levels correlated with clofibrate administration.
• Carnitine levels decreased upon cessation of clofibrate therapy.
• Increased carnitine levels were not associated with increased HDL-C.

Conclusions:

• Clofibrate therapy, in combination with probucol, can lead to elevated plasma carnitine levels.
• The observed increase in carnitine is reversible and not linked to HDL-C elevation.
• Carnitine metabolism may be influenced by clofibrate.